ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER
Latest Information Update: 02 May 2023
At a glance
- Drugs Onapristone (Primary) ; Letrozole; Palbociclib
- Indications Advanced breast cancer
- Focus Adverse reactions
- 26 Apr 2023 Status changed from recruiting to withdrawn prior to enrolment. The sponsor closed the study due to discontinuing their onapristone program.
- 10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium
- 11 Aug 2022 According to a Context Therapeutics media release, enrollment continues primarily due to slower than anticipated patient enrollment and preliminary data from the Phase 1b portion of the trial is expected in mid 2023.